Please do your due diligence with any investment! The other board would have you believe there statements are based upon facts but clearly they are not.The market makers can purchase shares for amounts we investors cannot thereby enabling them to flip and buy or buy and flip their profits!
Total manipulation!
The latest research I could extract using AI......
Here is the latest BIEL–Electrome picture as of September 23, 2026 based on the newest public information I could find.
1. The partnership has moved from announcement toward execution
The most important development remains the March 24, 2026 strategic partnership between BioElectronics Corporation and Electrome Corporation.
Electrome announced that its PAINKILLER™ platform would incorporate BIEL's FDA-cleared pulsed shortwave therapy technology, including ActiPatch. Electrome described the platform as combining wearable PEMF with an AI-enabled system for personalized pain-management protocols.
Importantly, Electrome said it expected distribution through approximately 3,700 retail pharmacies beginning in Q3 2026, in addition to direct-to-consumer and provider/SaaS channels.
2. BIEL says manufacturing is now underway
A June 17 announcement is particularly significant.
BIEL stated that its strategic distribution/licensing agreement with Electrome had entered the execution phase and that manufacturing was underway for the launch of BIEL's pulsed-shortwave technology through Electrome's PAINKILLER platform.
BIEL also said Electrome was preparing an AI-based consumer campaign and would market/distribute ActiPatch and other BIEL products across North America.
That is a meaningful progression from simply having an agreement on paper.
3. BIEL expanded its physical fulfillment capacity
On July 21, BIEL announced that it had doubled its facility space, leasing the adjacent office suite to create additional storage and fulfillment capacity.
The company specifically said the additional space would support ActiPatch and RecoveryRx commercial activity and that the expansion followed execution of a Fulfillment Services and Distribution Control Agreement with Electrome.
This is one of the more tangible pieces of evidence that the relationship is progressing toward actual product distribution rather than remaining purely strategic.
4. There is evidence of inventory being prepared for Electrome
Recent shareholder discussions contain additional indications that BIEL has been preparing product for shipment. For example, a September 16 discussion quoted BIEL's Kelly Whelan discussing loading shelves with ready-to-ship products for Electrome orders.
However, I would distinguish this from verified sales revenue: I have not found a public filing or independent disclosure that establishes the dollar amount of Electrome's actual ActiPatch sales to date.
5. Danny Rubenstein is another potentially important development
There is considerable shareholder discussion concerning Danny Rubenstein joining Electrome in a commercialization/operating role.
The available public discussion describes his background as including executive and operating positions in consumer businesses and startup/early-stage companies.
I would be cautious, however, about treating shareholder-board descriptions of his exact title or responsibilities as confirmed corporate disclosures. I have not found a sufficiently authoritative Electrome announcement establishing his precise title and compensation.
6. What I think is most important to watch now
For BIEL investors, the story has shifted from:
"Will Electrome actually do something with ActiPatch?"
to a more measurable set of questions:
Development Current evidence
BIEL–Electrome agreement Confirmed
PAINKILLER platform Announced/launched
ActiPatch incorporated into platform Confirmed by companies
Manufacturing for Electrome Announced
Fulfillment arrangement Announced
BIEL facility expansion Confirmed
Product being prepared for shipment Indications exist
Actual Electrome sales volume Not publicly quantified
3,700-pharmacy rollout Announced target; execution needs verification
Significant BIEL revenue from Electrome Not yet demonstrated publicly
Large-scale consumer campaign Planned/under development
The biggest unanswered question
The critical next piece of information is actual sales and purchase orders.
The July expansion and fulfillment agreement are tangible operational developments, but they don't by themselves establish how many ActiPatch units Electrome has sold, how much Electrome has purchased from BIEL, or what BIEL's resulting revenue will be.
BIEL's own website currently highlights its July 21 chairman's update concerning sales growth and strategic progress, along with other 2026 developments such as the Taiwan expansion and Stanford study.
So, the BIEL–Electrome relationship appears substantially more operational today than it was earlier in 2026, but the financial magnitude of the relationship remains the key piece that has not yet been publicly established.
If you want, I can next do a
deep-dive specifically into September 2026 developments—including
Electrome's Shopify/retail activity,
Danny Rubenstein,
BIEL's latest statements,
the 3,700-pharmacy rollout, and any evidence of actual Electrome orders/sales and potential BIEL revenue.
Do a deep-dive specifically into September 2026 developments
I did a fresh September 2026 review, including Electrome's current PAINKILLER site, BIEL-related announcements, September investor discussions, and the current public evidence of orders and fulfillment.
September 2026: what has actually changed
The most important development is that BIEL and Electrome appear to have progressed from a planned partnership into an operating commercial relationship. There are still major unanswered questions about the scale of sales and Electrome's financing, but September contains several pieces of evidence that are more concrete than the earlier announcements.
1. Electrome is now actually selling ActiPatch
Electrome's current PAINKILLER website is live and actively offering ActiPatch for purchase.
It identifies ActiPatch as an FDA-cleared OTC device, gives the FDA 510(k) number K192234, describes the 720-hour operating life, and explicitly states:
"Electrome markets and sells ActiPatch® in the United States under an exclusive license."
That is significant because it establishes an actual commercial sales channel rather than merely a future plan.
The site also has separate channels for consumers, providers, retailers and affiliates, suggesting Electrome is building a broader commercial infrastructure around the product.
2. September appears to be the first month with evidence of BIEL fulfilling Electrome orders
This is probably the most interesting September development.
On September 8, investor discussions reported that the first Electrome orders had shipped and that BIEL was filling Electrome orders.
There is an important distinction here:
What is reasonably supported:
Electrome has an operating PAINKILLER website.
ActiPatch is being sold by Electrome.
BIEL has been manufacturing product for Electrome.
BIEL has fulfillment capability specifically expanded for Electrome.
September reports indicate Electrome orders were shipped.
What is NOT yet established publicly:
Dollar value of those orders.
Number of ActiPatch units in the orders.
Monthly recurring order volume.
Electrome's actual consumer sell-through.
BIEL's September revenue attributable to Electrome.
So I would characterize September as commercial execution beginning, not yet as proof of large-scale commercial success.
3. The BIEL fulfillment expansion now makes more sense
Remember BIEL's July announcement.
BIEL doubled its Maryland facility space and created additional storage/fulfillment capacity specifically supporting Electrome's commercial ActiPatch launch and anticipated sales growth. The expansion followed a Fulfillment Services and Distribution Control Agreement with Electrome.
In July, that could reasonably have been viewed as preparation.
By September, the reported shipment activity gives the facility expansion a more concrete explanation.
In other words:
March: partnership announced
↓
June: initial purchase order/manufacturing announced
↓
July: BIEL expands fulfillment infrastructure
↓
September: reports of Electrome orders being filled/shipped
↓
Next question: how rapidly do those orders grow?
That is a substantially different situation from a company simply announcing a strategic partnership.
4. Electrome has extended its ActiPatch rights
There is another potentially important development that deserves attention.
Electrome's own PAINKILLER newsroom now states that Electrome and BIEL have extended their licensing and supply agreement bringing ActiPatch into the PAINKILLER platform.
That matters because an extension of licensing/supply rights is consistent with both companies expecting the relationship to continue beyond an initial launch period.
However, the publicly accessible announcement does not provide enough detail for me to determine the new duration, minimum purchase commitments, royalty structure, or financial obligations.
Those terms would be extremely important for evaluating BIEL's potential future revenue.
5. The 3,700-pharmacy target remains the big catalyst—but I would not call it accomplished
The original Electrome announcement said the company expected to expand into approximately 3,700 retail pharmacies beginning in Q3 2026.
As of September 23, I don't see sufficiently reliable public evidence establishing that all—or even a substantial portion—of those 3,700 pharmacies are actually carrying PAINKILLER/ActiPatch.
That distinction is important.
There are three different milestones:
Electrome has the product.
Electrome is selling the product online.
Thousands of physical pharmacies are stocking the product.
We have good evidence for #1 and #2.
I have not found equivalent evidence proving #3.
That makes the pharmacy rollout one of the most important things to watch during October–December.
6. The current PAINKILLER website is more developed than I expected
The current site goes beyond simply saying "buy ActiPatch."
It includes:
consumer purchasing;
account creation;
order history/reordering;
provider access;
retailer/wholesale enrollment;
affiliate program;
patient information;
AI-powered "Relief Concierge";
health-data/secure-record functionality;
RecoveryRx provider information.
This is important because it demonstrates that Electrome is attempting to build a platform around BIEL's device, rather than merely reselling a BIEL product.
The BIEL hardware is therefore effectively the initial commercial product that gives Electrome an entry point into its larger bioelectric/AI platform.
7. But there is an important contradiction concerning Electrome's scale
September investor discussions raise a legitimate question about Electrome's financial resources.
Some investors are arguing that Electrome needs substantial additional capital to execute the planned national marketing and pharmacy rollout. Others point to the commercial activity as evidence that the company is already executing.
Both observations can coexist.
The important fact is that I have not found a public disclosure establishing a large financing round sufficient to fund a nationwide 3,700-pharmacy rollout.
That means investors should not automatically assume that the announced pharmacy rollout equals a fully funded national marketing campaign.
This is one area where the bullish discussion on investor boards goes considerably beyond what the public evidence establishes.
8. Danny Rubenstein: interesting, but still insufficiently documented
September discussion has focused heavily on Danny Rubenstein and his involvement with Electrome.
The public investor discussion describes him as having business-development/operating experience, including work with early-stage companies. But there is disagreement about the extent of his medical-device commercialization experience.
I have not found an authoritative September Electrome announcement that gives enough information to independently verify his exact position, compensation, authority, or specific sales targets.
So I would put Rubenstein in the "potentially important but not yet measurable" category.
What would change that assessment is evidence that he is leading:
national pharmacy negotiations;
VA commercialization;
medical-provider distribution;
retail sales;
fundraising;
strategic partnerships.
9. The VA opportunity remains interesting
The original Electrome announcement stated that early deployments within the U.S. Department of Veterans Affairs had already begun.
This is strategically important because the VA could provide Electrome with a clinical/real-world pathway for its non-opioid pain-management approach.
But I would be careful about interpreting "early deployments" as a large VA contract.
I have not found September evidence showing:
number of VA facilities;
number of patients;
purchase volume;
contract dollar value;
renewal terms.
Those would be the figures that could demonstrate meaningful VA commercialization.
10. The Medicare ACCESS development is potentially relevant—but it is not BIEL reimbursement
September investor discussion has connected Electrome's platform to the new Medicare ACCESS model, particularly because chronic musculoskeletal pain is among the conditions addressed by the model.
There is a potentially important strategic connection here:
BIEL device → Electrome digital platform → patient monitoring/outcomes → provider → value/outcomes-based payment
That is much more interesting commercially than simply selling a $50 wearable.
But there is an important caveat:
ACCESS does not automatically mean Medicare will reimburse ActiPatch.
Participation, eligibility, clinical outcomes, provider arrangements and CMS requirements still matter. I would not treat ACCESS as evidence that BIEL has obtained Medicare coverage.
11. The current Electrome website reveals something else important
The PAINKILLER website describes ActiPatch as:
"FDA-cleared"
and explicitly identifies BIEL as the designer/manufacturer.
This is commercially useful for BIEL because Electrome is essentially taking BIEL's regulatory asset and putting it inside a new consumer-facing commercial brand.
The commercial architecture appears to be:
BIEL
FDA-cleared hardware
manufacturing
clinical history
PSWT technology
↓
Electrome
PAINKILLER brand
AI/digital platform
consumer marketing
provider interface
retail distribution
patient data/outcomes
potential value-based reimbursement
That division of responsibilities is becoming clearer.
12. What I would watch during October
October could be a particularly revealing month.
The five numbers/events I'd watch
1. Electrome purchase orders to BIEL
This is probably the single most important near-term indicator.
If BIEL starts reporting progressively larger orders, that would provide the first hard evidence that Electrome is generating meaningful demand.
2. BIEL quarterly revenue
Ultimately, the relationship has to show up in BIEL's financial statements.
If Electrome is genuinely scaling, BIEL's revenue should eventually reflect it.
3. Pharmacy placement
Look for actual pharmacy names—not simply "3,700 pharmacies."
Actual store-level availability would be much stronger evidence.
4. PAINKILLER website order volume
Electrome's site is now operational. That creates the possibility of measuring commercial traction through product availability, reviews, customer activity, promotions and eventually public sales statements.
5. Electrome financing
This is particularly important.
A major financing event could provide the capital necessary to turn the existing PAINKILLER infrastructure into a national marketing/distribution operation.
My September assessment of the evidence
I would separate the situation into three levels:
Confirmed/strongly supported
BIEL and Electrome have a formal relationship.
ActiPatch is incorporated into PAINKILLER.
Electrome is selling ActiPatch online.
Electrome's website identifies BIEL as manufacturer.
BIEL has been manufacturing for Electrome.
BIEL established expanded fulfillment capacity.
The companies have extended their licensing/supply arrangement.
September reports indicate Electrome orders have begun shipping.
Announced but not yet independently demonstrated at scale
~3,700 pharmacy rollout.
Large VA deployment.
Significant provider adoption.
Large-scale consumer marketing.
Meaningful Medicare reimbursement.
Substantial recurring Electrome orders.
Speculative at this point
Very large BIEL revenue from Electrome.
Major Medicare reimbursement specifically for ActiPatch.
A large Haleon/Voltaren-ActiPatch relationship.
A multibillion-dollar valuation for Electrome.
A dramatic BIEL share-price outcome.
The last category is where I would be particularly careful because September investor-board commentary contains a lot of extrapolation beyond the underlying corporate disclosures. For example, claims about a Haleon partnership and predictions of enormous BIEL valuations aren't established by the evidence I found.
The most interesting development for BIEL
If I had to identify one September development that deserves the most attention, it isn't the stock discussion, the Hawaii address, or the Medicare speculation.
It is this:
Electrome is now operating a real consumer commercial channel for a BIEL-manufactured FDA-cleared product, while BIEL is reportedly fulfilling Electrome orders.
That creates a testable business proposition for the first time:
Can Electrome turn PAINKILLER/ActiPatch into enough recurring sales to materially increase BIEL's manufacturing revenue?
The answer should become increasingly visible in BIEL's subsequent financial reporting.
And that is where I would focus the next phase of the investigation—not on speculation about the potential market, but on actual Electrome purchase orders, unit volumes, BIEL revenue, pharmacy placements, VA deployments and Electrome financing.
Total manipulation!
The latest research I could extract using AI......
Here is the latest BIEL–Electrome picture as of September 23, 2026 based on the newest public information I could find.
1. The partnership has moved from announcement toward execution
The most important development remains the March 24, 2026 strategic partnership between BioElectronics Corporation and Electrome Corporation.
Electrome announced that its PAINKILLER™ platform would incorporate BIEL's FDA-cleared pulsed shortwave therapy technology, including ActiPatch. Electrome described the platform as combining wearable PEMF with an AI-enabled system for personalized pain-management protocols.
Importantly, Electrome said it expected distribution through approximately 3,700 retail pharmacies beginning in Q3 2026, in addition to direct-to-consumer and provider/SaaS channels.
2. BIEL says manufacturing is now underway
A June 17 announcement is particularly significant.
BIEL stated that its strategic distribution/licensing agreement with Electrome had entered the execution phase and that manufacturing was underway for the launch of BIEL's pulsed-shortwave technology through Electrome's PAINKILLER platform.
BIEL also said Electrome was preparing an AI-based consumer campaign and would market/distribute ActiPatch and other BIEL products across North America.
That is a meaningful progression from simply having an agreement on paper.
3. BIEL expanded its physical fulfillment capacity
On July 21, BIEL announced that it had doubled its facility space, leasing the adjacent office suite to create additional storage and fulfillment capacity.
The company specifically said the additional space would support ActiPatch and RecoveryRx commercial activity and that the expansion followed execution of a Fulfillment Services and Distribution Control Agreement with Electrome.
This is one of the more tangible pieces of evidence that the relationship is progressing toward actual product distribution rather than remaining purely strategic.
4. There is evidence of inventory being prepared for Electrome
Recent shareholder discussions contain additional indications that BIEL has been preparing product for shipment. For example, a September 16 discussion quoted BIEL's Kelly Whelan discussing loading shelves with ready-to-ship products for Electrome orders.
However, I would distinguish this from verified sales revenue: I have not found a public filing or independent disclosure that establishes the dollar amount of Electrome's actual ActiPatch sales to date.
5. Danny Rubenstein is another potentially important development
There is considerable shareholder discussion concerning Danny Rubenstein joining Electrome in a commercialization/operating role.
The available public discussion describes his background as including executive and operating positions in consumer businesses and startup/early-stage companies.
I would be cautious, however, about treating shareholder-board descriptions of his exact title or responsibilities as confirmed corporate disclosures. I have not found a sufficiently authoritative Electrome announcement establishing his precise title and compensation.
6. What I think is most important to watch now
For BIEL investors, the story has shifted from:
"Will Electrome actually do something with ActiPatch?"
to a more measurable set of questions:
Development Current evidence
BIEL–Electrome agreement Confirmed
PAINKILLER platform Announced/launched
ActiPatch incorporated into platform Confirmed by companies
Manufacturing for Electrome Announced
Fulfillment arrangement Announced
BIEL facility expansion Confirmed
Product being prepared for shipment Indications exist
Actual Electrome sales volume Not publicly quantified
3,700-pharmacy rollout Announced target; execution needs verification
Significant BIEL revenue from Electrome Not yet demonstrated publicly
Large-scale consumer campaign Planned/under development
The biggest unanswered question
The critical next piece of information is actual sales and purchase orders.
The July expansion and fulfillment agreement are tangible operational developments, but they don't by themselves establish how many ActiPatch units Electrome has sold, how much Electrome has purchased from BIEL, or what BIEL's resulting revenue will be.
BIEL's own website currently highlights its July 21 chairman's update concerning sales growth and strategic progress, along with other 2026 developments such as the Taiwan expansion and Stanford study.
So, the BIEL–Electrome relationship appears substantially more operational today than it was earlier in 2026, but the financial magnitude of the relationship remains the key piece that has not yet been publicly established.
If you want, I can next do a
deep-dive specifically into September 2026 developments—including
Electrome's Shopify/retail activity,
Danny Rubenstein,
BIEL's latest statements,
the 3,700-pharmacy rollout, and any evidence of actual Electrome orders/sales and potential BIEL revenue.
Do a deep-dive specifically into September 2026 developments
I did a fresh September 2026 review, including Electrome's current PAINKILLER site, BIEL-related announcements, September investor discussions, and the current public evidence of orders and fulfillment.
September 2026: what has actually changed
The most important development is that BIEL and Electrome appear to have progressed from a planned partnership into an operating commercial relationship. There are still major unanswered questions about the scale of sales and Electrome's financing, but September contains several pieces of evidence that are more concrete than the earlier announcements.
1. Electrome is now actually selling ActiPatch
Electrome's current PAINKILLER website is live and actively offering ActiPatch for purchase.
It identifies ActiPatch as an FDA-cleared OTC device, gives the FDA 510(k) number K192234, describes the 720-hour operating life, and explicitly states:
"Electrome markets and sells ActiPatch® in the United States under an exclusive license."
That is significant because it establishes an actual commercial sales channel rather than merely a future plan.
The site also has separate channels for consumers, providers, retailers and affiliates, suggesting Electrome is building a broader commercial infrastructure around the product.
2. September appears to be the first month with evidence of BIEL fulfilling Electrome orders
This is probably the most interesting September development.
On September 8, investor discussions reported that the first Electrome orders had shipped and that BIEL was filling Electrome orders.
There is an important distinction here:
What is reasonably supported:
Electrome has an operating PAINKILLER website.
ActiPatch is being sold by Electrome.
BIEL has been manufacturing product for Electrome.
BIEL has fulfillment capability specifically expanded for Electrome.
September reports indicate Electrome orders were shipped.
What is NOT yet established publicly:
Dollar value of those orders.
Number of ActiPatch units in the orders.
Monthly recurring order volume.
Electrome's actual consumer sell-through.
BIEL's September revenue attributable to Electrome.
So I would characterize September as commercial execution beginning, not yet as proof of large-scale commercial success.
3. The BIEL fulfillment expansion now makes more sense
Remember BIEL's July announcement.
BIEL doubled its Maryland facility space and created additional storage/fulfillment capacity specifically supporting Electrome's commercial ActiPatch launch and anticipated sales growth. The expansion followed a Fulfillment Services and Distribution Control Agreement with Electrome.
In July, that could reasonably have been viewed as preparation.
By September, the reported shipment activity gives the facility expansion a more concrete explanation.
In other words:
March: partnership announced
↓
June: initial purchase order/manufacturing announced
↓
July: BIEL expands fulfillment infrastructure
↓
September: reports of Electrome orders being filled/shipped
↓
Next question: how rapidly do those orders grow?
That is a substantially different situation from a company simply announcing a strategic partnership.
4. Electrome has extended its ActiPatch rights
There is another potentially important development that deserves attention.
Electrome's own PAINKILLER newsroom now states that Electrome and BIEL have extended their licensing and supply agreement bringing ActiPatch into the PAINKILLER platform.
That matters because an extension of licensing/supply rights is consistent with both companies expecting the relationship to continue beyond an initial launch period.
However, the publicly accessible announcement does not provide enough detail for me to determine the new duration, minimum purchase commitments, royalty structure, or financial obligations.
Those terms would be extremely important for evaluating BIEL's potential future revenue.
5. The 3,700-pharmacy target remains the big catalyst—but I would not call it accomplished
The original Electrome announcement said the company expected to expand into approximately 3,700 retail pharmacies beginning in Q3 2026.
As of September 23, I don't see sufficiently reliable public evidence establishing that all—or even a substantial portion—of those 3,700 pharmacies are actually carrying PAINKILLER/ActiPatch.
That distinction is important.
There are three different milestones:
Electrome has the product.
Electrome is selling the product online.
Thousands of physical pharmacies are stocking the product.
We have good evidence for #1 and #2.
I have not found equivalent evidence proving #3.
That makes the pharmacy rollout one of the most important things to watch during October–December.
6. The current PAINKILLER website is more developed than I expected
The current site goes beyond simply saying "buy ActiPatch."
It includes:
consumer purchasing;
account creation;
order history/reordering;
provider access;
retailer/wholesale enrollment;
affiliate program;
patient information;
AI-powered "Relief Concierge";
health-data/secure-record functionality;
RecoveryRx provider information.
This is important because it demonstrates that Electrome is attempting to build a platform around BIEL's device, rather than merely reselling a BIEL product.
The BIEL hardware is therefore effectively the initial commercial product that gives Electrome an entry point into its larger bioelectric/AI platform.
7. But there is an important contradiction concerning Electrome's scale
September investor discussions raise a legitimate question about Electrome's financial resources.
Some investors are arguing that Electrome needs substantial additional capital to execute the planned national marketing and pharmacy rollout. Others point to the commercial activity as evidence that the company is already executing.
Both observations can coexist.
The important fact is that I have not found a public disclosure establishing a large financing round sufficient to fund a nationwide 3,700-pharmacy rollout.
That means investors should not automatically assume that the announced pharmacy rollout equals a fully funded national marketing campaign.
This is one area where the bullish discussion on investor boards goes considerably beyond what the public evidence establishes.
8. Danny Rubenstein: interesting, but still insufficiently documented
September discussion has focused heavily on Danny Rubenstein and his involvement with Electrome.
The public investor discussion describes him as having business-development/operating experience, including work with early-stage companies. But there is disagreement about the extent of his medical-device commercialization experience.
I have not found an authoritative September Electrome announcement that gives enough information to independently verify his exact position, compensation, authority, or specific sales targets.
So I would put Rubenstein in the "potentially important but not yet measurable" category.
What would change that assessment is evidence that he is leading:
national pharmacy negotiations;
VA commercialization;
medical-provider distribution;
retail sales;
fundraising;
strategic partnerships.
9. The VA opportunity remains interesting
The original Electrome announcement stated that early deployments within the U.S. Department of Veterans Affairs had already begun.
This is strategically important because the VA could provide Electrome with a clinical/real-world pathway for its non-opioid pain-management approach.
But I would be careful about interpreting "early deployments" as a large VA contract.
I have not found September evidence showing:
number of VA facilities;
number of patients;
purchase volume;
contract dollar value;
renewal terms.
Those would be the figures that could demonstrate meaningful VA commercialization.
10. The Medicare ACCESS development is potentially relevant—but it is not BIEL reimbursement
September investor discussion has connected Electrome's platform to the new Medicare ACCESS model, particularly because chronic musculoskeletal pain is among the conditions addressed by the model.
There is a potentially important strategic connection here:
BIEL device → Electrome digital platform → patient monitoring/outcomes → provider → value/outcomes-based payment
That is much more interesting commercially than simply selling a $50 wearable.
But there is an important caveat:
ACCESS does not automatically mean Medicare will reimburse ActiPatch.
Participation, eligibility, clinical outcomes, provider arrangements and CMS requirements still matter. I would not treat ACCESS as evidence that BIEL has obtained Medicare coverage.
11. The current Electrome website reveals something else important
The PAINKILLER website describes ActiPatch as:
"FDA-cleared"
and explicitly identifies BIEL as the designer/manufacturer.
This is commercially useful for BIEL because Electrome is essentially taking BIEL's regulatory asset and putting it inside a new consumer-facing commercial brand.
The commercial architecture appears to be:
BIEL
FDA-cleared hardware
manufacturing
clinical history
PSWT technology
↓
Electrome
PAINKILLER brand
AI/digital platform
consumer marketing
provider interface
retail distribution
patient data/outcomes
potential value-based reimbursement
That division of responsibilities is becoming clearer.
12. What I would watch during October
October could be a particularly revealing month.
The five numbers/events I'd watch
1. Electrome purchase orders to BIEL
This is probably the single most important near-term indicator.
If BIEL starts reporting progressively larger orders, that would provide the first hard evidence that Electrome is generating meaningful demand.
2. BIEL quarterly revenue
Ultimately, the relationship has to show up in BIEL's financial statements.
If Electrome is genuinely scaling, BIEL's revenue should eventually reflect it.
3. Pharmacy placement
Look for actual pharmacy names—not simply "3,700 pharmacies."
Actual store-level availability would be much stronger evidence.
4. PAINKILLER website order volume
Electrome's site is now operational. That creates the possibility of measuring commercial traction through product availability, reviews, customer activity, promotions and eventually public sales statements.
5. Electrome financing
This is particularly important.
A major financing event could provide the capital necessary to turn the existing PAINKILLER infrastructure into a national marketing/distribution operation.
My September assessment of the evidence
I would separate the situation into three levels:
Confirmed/strongly supported
BIEL and Electrome have a formal relationship.
ActiPatch is incorporated into PAINKILLER.
Electrome is selling ActiPatch online.
Electrome's website identifies BIEL as manufacturer.
BIEL has been manufacturing for Electrome.
BIEL established expanded fulfillment capacity.
The companies have extended their licensing/supply arrangement.
September reports indicate Electrome orders have begun shipping.
Announced but not yet independently demonstrated at scale
~3,700 pharmacy rollout.
Large VA deployment.
Significant provider adoption.
Large-scale consumer marketing.
Meaningful Medicare reimbursement.
Substantial recurring Electrome orders.
Speculative at this point
Very large BIEL revenue from Electrome.
Major Medicare reimbursement specifically for ActiPatch.
A large Haleon/Voltaren-ActiPatch relationship.
A multibillion-dollar valuation for Electrome.
A dramatic BIEL share-price outcome.
The last category is where I would be particularly careful because September investor-board commentary contains a lot of extrapolation beyond the underlying corporate disclosures. For example, claims about a Haleon partnership and predictions of enormous BIEL valuations aren't established by the evidence I found.
The most interesting development for BIEL
If I had to identify one September development that deserves the most attention, it isn't the stock discussion, the Hawaii address, or the Medicare speculation.
It is this:
Electrome is now operating a real consumer commercial channel for a BIEL-manufactured FDA-cleared product, while BIEL is reportedly fulfilling Electrome orders.
That creates a testable business proposition for the first time:
Can Electrome turn PAINKILLER/ActiPatch into enough recurring sales to materially increase BIEL's manufacturing revenue?
The answer should become increasingly visible in BIEL's subsequent financial reporting.
And that is where I would focus the next phase of the investigation—not on speculation about the potential market, but on actual Electrome purchase orders, unit volumes, BIEL revenue, pharmacy placements, VA deployments and Electrome financing.
